Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab
- PMID: 32503849
- DOI: 10.1136/annrheumdis-2020-217864
Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab
Keywords: inflammation; rituximab; scleroderma; systemic.
Conflict of interest statement
Competing interests: JA reports personal fees from Sanofi, Abbvie, Boerhinger, Nordic, Novartis, and grants and personal fees from Bristol Myers Squibb, Pfizer outside the submitted work; PA and NC have nothing to disclose. MM-C reports grant and personal fees from Actelion, Biogen, Bayer, Boehringer Ingelheim, CSL Behring and Eli-Lilly, outside the submitted work. YA reports personal fees from Actelion, Bayer, BMS, Boehringer Ingelheim and Curzion, and grants and personal fees from Inventiva, Roche and Sanofi.
Comment in
-
Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac et al.Ann Rheum Dis. 2021 Mar;80(3):e38. doi: 10.1136/annrheumdis-2020-217955. Epub 2020 Jun 5. Ann Rheum Dis. 2021. PMID: 32503848 No abstract available.
Comment on
-
Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.Ann Rheum Dis. 2021 Jan;80(1):e10. doi: 10.1136/annrheumdis-2020-217549. Epub 2020 Apr 20. Ann Rheum Dis. 2021. PMID: 32312768 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical